We keep saying that Biota is undervalued, which it is at current prices, so then it is logical that a share buyback is still a viable, and useful option to increase shareholder value.
At $1 and below, a buyback was a screaming bargain, at $2 it is still undervalued, thus would increase shareholder value. I would like to see a buyback below $2.20, and if Lani is a success, a buyback below $3.
Alternatively, if there are attractive options in new drug development, or speeding up the process of developing HRV, I agree that these would also be good options.
BTA Price at posting:
$1.91 Sentiment: LT Buy Disclosure: Held
